Apalutamide delays progression of nonmetastatic, castration-resistant prostate cancer

(Massachusetts General Hospital) A multi-institutional phase 3 trial led by investigators at Massachusetts General Hospital and University of California, San Francisco found that treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news